Study uncovers the TMPO-AS1/let-7b-5p/PLK1/E2F1 axis influencing poor outcomes in lung adenocarcinoma, suggesting new treatment avenues.
The study highlights the PLK1/E2F1/hsa-let-7b-5p/TMPO-AS1 regulatory axis as a key contributor to aggressive LUAD. Targeting this ceRNA network either by inhibiting TMPO-AS1 or restoring hsa-let-7b-5p activity may offer a promising strategy for therapeutic intervention in smoking-associated LUAD.
No takes yet. Share an insight, caveat, or question.
Baweja et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: